EGFR and non-small cell lung carcinoma: Aumolertinib, another third-generation EGFR-TKI, was evaluated originally after disease progression in patients with locally advanced or metastatic NSCLC who developed an EGFR T790M mutation after progression on first- or second-generation EGFR TKI therapy, in the APOLLO trial [45].